Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors

ABSTRACT To identify novel genetic bases of early‐onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A&g...

Full description

Saved in:
Bibliographic Details
Published inHuman mutation Vol. 35; no. 3; pp. 294 - 297
Main Authors Tournier, Isabelle, Marlin, Régine, Walton, Kelly, Charbonnier, Françoise, Coutant, Sophie, Théry, Jean-Christophe, Charbonnier, Camille, Spurrell, Cailyn, Vezain, Myriam, Ippolito, Lorena, Bougeard, Gaëlle, Roman, Horace, Tinat, Julie, Sabourin, Jean-Christophe, Stoppa-Lyonnet, Dominique, Caron, Olivier, Bressac-de Paillerets, Brigitte, Vaur, Dominique, King, Mary-Claire, Harrison, Craig, Frebourg, Thierry
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2014
Hindawi Limited
Wiley
BlackWell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ABSTRACT To identify novel genetic bases of early‐onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA‐subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early‐onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α‐subunit, the partner of the βA‐subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors. Using the trio exome sequencing strategy, we identified a germline de novo mutation of the INHBA gene in a patient who developed sporadic bilateral ovarian epithelial adenocarcinomas at 21 years of age and showed that this mutation affects the inhibin/activin ratio. Identification in patients with early‐onset ovarian tumors of other variations affecting this gene or its partner INHA, functional assays and statistical tests indicate that germline alterations of the inhibin/activin pathway may contribute to the genetic determinism of early‐onset epithelial ovarian tumors.
AbstractList To identify novel genetic bases of early-onsetepithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancerwho presented metastatic serous ovarian adenocarcinomasat 21 years of age. We identified a single de novo mutation(c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA-subunit of inhibins/activins, which play akey role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a secondpatient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation(c.179G>T/p.Arg60Leu) of the INHA gene encoding theα-subunit, the partner of the βA-subunit. This mutationalso alters the secreted activin/inhibin ratio, by disruptingboth inhibin A and inhibin B biosynthesis. In a cohort of62 cases, we detected an additional unreported germlinemutation of the INHBA gene (c.839G>A/p.Gly280Glu).Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovariantumors.
ABSTRACT To identify novel genetic bases of early‐onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA‐subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early‐onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α‐subunit, the partner of the βA‐subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors. Using the trio exome sequencing strategy, we identified a germline de novo mutation of the INHBA gene in a patient who developed sporadic bilateral ovarian epithelial adenocarcinomas at 21 years of age and showed that this mutation affects the inhibin/activin ratio. Identification in patients with early‐onset ovarian tumors of other variations affecting this gene or its partner INHA, functional assays and statistical tests indicate that germline alterations of the inhibin/activin pathway may contribute to the genetic determinism of early‐onset epithelial ovarian tumors.
To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α-subunit, the partner of the βA-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors.
To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the βA-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the α-subunit, the partner of the βA-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors.
To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the beta A-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the alpha -subunit, the partner of the beta A-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors. Using the trio exome sequencing strategy, we identified a germline de novo mutation of the INHBA gene in a patient who developed sporadic bilateral ovarian epithelial adenocarcinomas at 21 years of age and showed that this mutation affects the inhibin/activin ratio. Identification in patients with early-onset ovarian tumors of other variations affecting this gene or its partner INHA, functional assays and statistical tests indicate that germline alterations of the inhibin/activin pathway may contribute to the genetic determinism of early-onset epithelial ovarian tumors.
To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of cancer who presented metastatic serous ovarian adenocarcinomas at 21 years of age. We identified a single de novo mutation (c.1157A>G/p.Asn386Ser) within the INHBA gene encoding the [beta]A-subunit of inhibins/activins, which play a key role in ovarian development. In vitro, this mutation alters the ratio of secreted activins and inhibins. In a second patient with early-onset serous borderline papillary cystadenoma, we identified an unreported germline mutation (c.179G>T/p.Arg60Leu) of the INHA gene encoding the [alpha]-subunit, the partner of the [beta]A-subunit. This mutation also alters the secreted activin/inhibin ratio, by disrupting both inhibin A and inhibin B biosynthesis. In a cohort of 62 cases, we detected an additional unreported germline mutation of the INHBA gene (c.839G>A/p.Gly280Glu). Our results strongly suggest that inhibin mutations contribute to the genetic determinism of epithelial ovarian tumors.
Author Caron, Olivier
Ippolito, Lorena
Bressac-de Paillerets, Brigitte
Harrison, Craig
Roman, Horace
Théry, Jean-Christophe
King, Mary-Claire
Tinat, Julie
Marlin, Régine
Bougeard, Gaëlle
Sabourin, Jean-Christophe
Charbonnier, Françoise
Frebourg, Thierry
Vezain, Myriam
Tournier, Isabelle
Charbonnier, Camille
Stoppa-Lyonnet, Dominique
Walton, Kelly
Coutant, Sophie
Vaur, Dominique
Spurrell, Cailyn
Author_xml – sequence: 1
  givenname: Isabelle
  surname: Tournier
  fullname: Tournier, Isabelle
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 2
  givenname: Régine
  surname: Marlin
  fullname: Marlin, Régine
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 3
  givenname: Kelly
  surname: Walton
  fullname: Walton, Kelly
  organization: Growth Factor Signalling Laboratory, Prince Henry's Institute of Medical Research, Clayton, Australia
– sequence: 4
  givenname: Françoise
  surname: Charbonnier
  fullname: Charbonnier, Françoise
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 5
  givenname: Sophie
  surname: Coutant
  fullname: Coutant, Sophie
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 6
  givenname: Jean-Christophe
  surname: Théry
  fullname: Théry, Jean-Christophe
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 7
  givenname: Camille
  surname: Charbonnier
  fullname: Charbonnier, Camille
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 8
  givenname: Cailyn
  surname: Spurrell
  fullname: Spurrell, Cailyn
  organization: Department of Medicine and Genome Sciences, University of Washington School of Medicine, Washington, Seattle
– sequence: 9
  givenname: Myriam
  surname: Vezain
  fullname: Vezain, Myriam
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 10
  givenname: Lorena
  surname: Ippolito
  fullname: Ippolito, Lorena
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 11
  givenname: Gaëlle
  surname: Bougeard
  fullname: Bougeard, Gaëlle
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Cancéropôle Nord-Ouest, Rouen, France
– sequence: 12
  givenname: Horace
  surname: Roman
  fullname: Roman, Horace
  organization: Department of Gynaecology and Obstetrics, University Hospital of Rouen, Rouen, France
– sequence: 13
  givenname: Julie
  surname: Tinat
  fullname: Tinat, Julie
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, Cancéropôle Nord-Ouest, France
– sequence: 14
  givenname: Jean-Christophe
  surname: Sabourin
  fullname: Sabourin, Jean-Christophe
  organization: Department of Pathology, University Hospital of Rouen, Rouen, France
– sequence: 15
  givenname: Dominique
  surname: Stoppa-Lyonnet
  fullname: Stoppa-Lyonnet, Dominique
  organization: Department of Genetics, Inserm U830, Institut Curie, Paris Descartes University, Paris, France
– sequence: 16
  givenname: Olivier
  surname: Caron
  fullname: Caron, Olivier
  organization: Department of Genetics, Institut Gustave Roussy, France
– sequence: 17
  givenname: Brigitte
  surname: Bressac-de Paillerets
  fullname: Bressac-de Paillerets, Brigitte
  organization: Department of Genetics, Institut Gustave Roussy, France
– sequence: 18
  givenname: Dominique
  surname: Vaur
  fullname: Vaur, Dominique
  organization: Department of Cancer Genetics, Comprehensive Cancer Centre, Caen, France
– sequence: 19
  givenname: Mary-Claire
  surname: King
  fullname: King, Mary-Claire
  organization: Department of Medicine and Genome Sciences, University of Washington School of Medicine, Washington, Seattle
– sequence: 20
  givenname: Craig
  surname: Harrison
  fullname: Harrison, Craig
  organization: Growth Factor Signalling Laboratory, Prince Henry's Institute of Medical Research, Clayton, Australia
– sequence: 21
  givenname: Thierry
  surname: Frebourg
  fullname: Frebourg, Thierry
  email: frebourg@chu-rouen.fr
  organization: Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, Cancéropôle Nord-Ouest, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24302632$$D View this record in MEDLINE/PubMed
https://normandie-univ.hal.science/hal-02375836$$DView record in HAL
BookMark eNqFkU9vEzEQxS1URNvAhQ-AVuICSFv8Z-21L0hVW5KilFwSIfVieXdt1mXXDvZuIN8eh7QR9AAnj8a_eTN67xQcOe80AC8RPEMQ4vft2I9nGBdcPAEnCAqep3ZxtKupyMtSFMfgNMY7CCGnlDwDx7ggEDOCT8B0qkPfWaezm3FQg_UuZt5k1661lU21ddmVCt02X7ioh2yxUcGq1FvbodWdVV22HHsf4nPw1Kgu6hf37wSsPl4tL2b5fDG9vjif53XanI4xNeQENxWmTWlQQSgjlTCE1YI2iuimwdoYhU1FKS-5waZEnOsKMSQaqhWZgA973fVY9bqptRuC6uQ62F6FrfTKyr9_nG3lV7-RBeZFMiAJvN0LtI_GZudzuetBTErKCdugxL65Xxb891HHQfY21rrrlNN-jBJRBhFiUIj_o4UQiJJ0REJfP0Lv_Bhcck0iRkUpSp48moB3e6oOPsagzeFYBOUudrmLXf6OPcGv_nTlgD7knAC0B37YTm__ISVnq5vVg2i-n7Fx0D8PMyp8k6xMHskvn6fy9lOxJJfsVl6SX25QyAs
CitedBy_id crossref_primary_10_1080_14728222_2020_1799350
crossref_primary_10_3389_fgene_2021_705512
crossref_primary_10_1002_ijc_30476
crossref_primary_10_1210_endocr_bqaa184
crossref_primary_10_1530_EJE_22_0330
crossref_primary_10_18632_oncotarget_28358
crossref_primary_10_26416_Gine_29_3_2020_4063
crossref_primary_10_1016_j_biocel_2024_106570
crossref_primary_10_1371_journal_pone_0090575
crossref_primary_10_1158_1078_0432_CCR_19_1065
Cites_doi 10.1371/journal.pgen.1000384
10.1074/jbc.M801045200
10.1038/ejhg.2011.258
10.1038/nrg3241
10.1038/ng.893
10.1074/jbc.M110.177865
10.1158/0008-5472.CAN-04-3553
10.1186/1471-2105-13-S14-S9
10.1186/gb-2011-12-9-227
10.1038/nature10166
10.1016/j.mce.2011.06.030
10.1016/j.ajhg.2008.06.024
10.1371/journal.pgen.1001322
10.1038/nature10945
10.1038/360313a0
10.1016/j.mrfmmm.2006.09.003
10.1016/j.canlet.2009.05.010
10.1016/j.mce.2011.04.024
10.1016/j.molonc.2009.02.004
10.1073/pnas.1115052108
10.1038/ng.712
10.1016/j.ajhg.2011.05.029
ContentType Journal Article
Copyright 2013 The Authors. * published by Wiley Periodicals, Inc.
2013 The Authors. *Human Mutation published by Wiley Periodicals, Inc.
Copyright © 2014 Wiley Periodicals, Inc.
Attribution - NonCommercial - NoDerivatives
2013 The Authors. * published by Wiley Periodicals, Inc. 2013
Copyright_xml – notice: 2013 The Authors. * published by Wiley Periodicals, Inc.
– notice: 2013 The Authors. *Human Mutation published by Wiley Periodicals, Inc.
– notice: Copyright © 2014 Wiley Periodicals, Inc.
– notice: Attribution - NonCommercial - NoDerivatives
– notice: 2013 The Authors. * published by Wiley Periodicals, Inc. 2013
DBID BSCLL
24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TK
8FD
FR3
K9.
P64
RC3
7X8
1XC
VOOES
5PM
DOI 10.1002/humu.22489
DatabaseName Istex
Wiley_OA刊
Wiley Online Library Journals
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Genetics Abstracts
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList

MEDLINE

Genetics Abstracts
Genetics Abstracts
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley-Blackwell Titles (Open access)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-1004
EndPage 297
ExternalDocumentID oai_HAL_hal_02375836v1
3610743021
10_1002_humu_22489
24302632
HUMU22489
ark_67375_WNG_ZJ4T3D6Z_D
Genre shortCommunication
Journal Article
GrantInformation_xml – fundername: INCa
– fundername: Fondation pour la Recherche Medicale
– fundername: French National Cancer Institute
– fundername: NCI NIH HHS
  grantid: R01 CA157744
– fundername: NCI NIH HHS
  grantid: R01 CA175716
– fundername: NCI NIH HHS
  grantid: R35 CA197458
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
29I
31~
33P
3SF
3V.
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
88A
88E
8C1
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAJEY
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHUG
ABIJN
ABJNI
ABPVW
ABUWG
ABWRO
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEQTP
AEUQT
AFBPY
AFGKR
AFKRA
AFPWT
AFVGU
AFZJQ
AGJLS
AHMBA
AIURR
AIWBW
AJAOE
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BBNVY
BDRZF
BENPR
BFHJK
BHBCM
BHPHI
BMNLL
BMXJE
BNHUX
BPHCQ
BROTX
BRXPI
BSCLL
BVXVI
BY8
C45
CCPQU
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
DVXWH
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FYUFA
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HCIFZ
HF~
HHY
HHZ
HMCUK
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LK8
LOXES
LP6
LP7
LUTES
LW6
LYRES
M0L
M1P
M66
M7P
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OVD
P2P
P2W
P2X
P4D
PALCI
PIMPY
PQQKQ
PROAC
PSQYO
Q.N
Q11
Q2X
QB0
QRW
R.K
RHX
RIWAO
RJQFR
ROL
RWI
RWV
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
UDS
UKHRP
V2E
W8V
W99
WBKPD
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WTM
WXSBR
WYISQ
X7M
XG1
XSW
XV2
ZZTAW
~IA
~KM
~WT
24P
ALIPV
ALUQN
H13
OIG
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TK
8FD
FR3
K9.
P64
RC3
7X8
1XC
VOOES
5PM
ID FETCH-LOGICAL-c5539-7fc0832db25d7f143563b9f36c95da3edd2effa2fb55878f2f7188eb1619d5ea3
IEDL.DBID DR2
ISSN 1059-7794
IngestDate Tue Sep 17 21:24:39 EDT 2024
Tue Oct 15 15:46:47 EDT 2024
Fri Aug 16 07:33:04 EDT 2024
Fri Aug 16 21:39:01 EDT 2024
Thu Oct 10 22:03:47 EDT 2024
Fri Aug 23 00:45:05 EDT 2024
Sat Sep 28 08:34:11 EDT 2024
Sat Aug 24 00:39:26 EDT 2024
Wed Jan 17 05:00:06 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords ovary
exome
activin
cancer
INHBA
INHA
inhibin
Exome
Ovary
Inhibin
Activin
Cancer
Language English
License Attribution-NonCommercial-NoDerivs
2013 The Authors. *Human Mutation published by Wiley Periodicals, Inc.
Attribution - NonCommercial - NoDerivatives: http://creativecommons.org/licenses/by-nc-nd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5539-7fc0832db25d7f143563b9f36c95da3edd2effa2fb55878f2f7188eb1619d5ea3
Notes INCa
ArticleID:HUMU22489
istex:136B0BC49B1DB2C491E7936F018CE476D5FE2971
Fondation pour la Recherche Medicale
French National Cancer Institute
ark:/67375/WNG-ZJ4T3D6Z-D
Communicated by David E. Goldgar
Contract grant sponsors: INCa; French National Cancer Institute; Fondation pour la Recherche Medicale.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ORCID 0000-0002-9237-0628
0000-0002-5438-8309
0000-0003-0399-4007
0000-0002-8333-1360
0000-0002-1475-0254
0000-0002-5544-048X
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhumu.22489
PMID 24302632
PQID 1659797808
PQPubID 30498
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4284000
hal_primary_oai_HAL_hal_02375836v1
proquest_miscellaneous_1560116099
proquest_miscellaneous_1499153284
proquest_journals_1659797808
crossref_primary_10_1002_humu_22489
pubmed_primary_24302632
wiley_primary_10_1002_humu_22489_HUMU22489
istex_primary_ark_67375_WNG_ZJ4T3D6Z_D
PublicationCentury 2000
PublicationDate March 2014
PublicationDateYYYYMMDD 2014-03-01
PublicationDate_xml – month: 03
  year: 2014
  text: March 2014
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
– name: Oxford, UK
PublicationTitle Human mutation
PublicationTitleAlternate Human Mutation
PublicationYear 2014
Publisher Blackwell Publishing Ltd
Hindawi Limited
Wiley
BlackWell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
– name: Hindawi Limited
– name: Wiley
– name: BlackWell Publishing Ltd
References Veltman JA, Brunner HG. 2012. De novo mutations in human genetic disease. Nat Rev Genet 13:565-575.
Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A. 1992. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319.
Morgenthaler S, Thilly WG. 2007. A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: a cohort allelic sums test (CAST). Mutat Res 615:28-56.
Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. 2005. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 65:7968-7975.
Knight PG, Satchell L, Glister C. 2012. Intra-ovarian roles of activins and inhibins. Mol Cell Endocrinol 359:53-65.
Li S, Shimono C, Norioka N, Nakano I, Okubo T, Yagi Y, Hayashi M, Sato Y, Fujisaki H, Hattori S, Sugiura N, Kimata K, et al. 2010. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J Biol Chem 285:36645-36655.
Coutant S, Cabot C, Lefebvre A, Léonard M, Prieur-Gaston E, Campion D, Lecroq T, Dauchel H. 2012. EVA: Exome Variation Analyzer, an efficient and versatile tool for filtering strategies in medical genomics. BMC Bioinformatics 13 Suppl 14:S9.
Stitziel NO, Kiezun A, Sunyaev S. 2011. Computational and statistical approaches to analyzing variants identified by exome sequencing. Genome Biol 12:227.
Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, et al. 2011. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43:879-882.
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, et al. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 108:18032-18037.
Neale BM, Rivas MA, Voight BF, Altshuler D, Devlin B, Orho-Melander M, Kathiresan S, Purcell SM, Roeder K, Daly MJ. 2011. Testing for an unusual distribution of rare variants. PLoS Genet 7:e1001322.
Gilissen C, Hoischen A, Brunner HG, Veltman JA. 2012. Disease gene identification strategies for exome sequencing. Eur J Hum Genet 20:490-497.
Madsen BE, Browning SR. 2009. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet 5:e1000384.
Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BW, Hoischen A, et al. 2010. A de novo paradigm for mental retardation. Nat Genet 42:1109-1112.
Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. 2009. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3:97-137.
The Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
Walton KL, Makanji Y, Harrison CA. 2012. New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol 359:2-12.
Makanji Y, Walton KL, Wilce MC, Chan KL, Robertson DM, Harrison CA. 2008. Suppression of inhibin A biological activity by alterations in the binding site for betaglycan. J Biol Chem 283:16743-16751.
Ramachandran A, Marshall ES, Love DR, Baguley BC, Shelling AN. 2009. Activin is a potent growth suppressor of epithelial ovarian cancer cells. Cancer Lett 285:157-165.
Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Senciek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, et al. 2012. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485:237-241.
Li B, Leal SM. 2008. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am J Hum Genet 83:311-321.
Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. 2011. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 89:82-93.
2010; 42
2012; 485
2011; 108
1992; 360
2005; 65
2010; 285
2011; 43
2011; 12
2011; 89
2009; 5
2009; 285
2008; 83
2009; 3
2012; 13
2007; 615
2012; 359
2012; 20
2008; 283
2011; 7
2011; 474
e_1_2_3_2_1
e_1_2_3_6_1
e_1_2_3_16_1
e_1_2_3_5_1
e_1_2_3_17_1
e_1_2_3_4_1
e_1_2_3_18_1
e_1_2_3_3_1
e_1_2_3_19_1
e_1_2_3_12_1
e_1_2_3_23_1
e_1_2_3_9_1
e_1_2_3_13_1
e_1_2_3_8_1
e_1_2_3_14_1
e_1_2_3_7_1
e_1_2_3_15_1
e_1_2_3_20_1
e_1_2_3_10_1
e_1_2_3_21_1
e_1_2_3_11_1
e_1_2_3_22_1
References_xml – volume: 83
  start-page: 311
  year: 2008
  end-page: 321
  article-title: Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data
  publication-title: Am J Hum Genet
– volume: 12
  start-page: 227
  year: 2011
  article-title: Computational and statistical approaches to analyzing variants identified by exome sequencing
  publication-title: Genome Biol
– volume: 474
  start-page: 609
  year: 2011
  end-page: 615
  article-title: Integrated genomic analyses of ovarian carcinoma
  publication-title: Nature
– volume: 42
  start-page: 1109
  year: 2010
  end-page: 1112
  article-title: A de novo paradigm for mental retardation
  publication-title: Nat Genet
– volume: 43
  start-page: 879
  year: 2011
  end-page: 882
  article-title: Germline mutations in 51 confer susceptibility to ovarian cancer
  publication-title: Nat Genet
– volume: 89
  start-page: 82
  year: 2011
  end-page: 93
  article-title: Rare‐variant association testing for sequencing data with the sequence kernel association test
  publication-title: Am J Hum Genet
– volume: 65
  start-page: 7968
  year: 2005
  end-page: 7975
  article-title: Activin mediates growth inhibition and cell cycle arrest through mads in human breast cancer cells
  publication-title: Cancer Res
– volume: 13
  start-page: 565
  year: 2012
  end-page: 575
  article-title: De novo mutations in human genetic disease
  publication-title: Nat Rev Genet
– volume: 13
  start-page: S9
  issue: Suppl 14
  year: 2012
  article-title: : xome ariation nalyzer, an efficient and versatile tool for filtering strategies in medical genomics
  publication-title: BMC Bioinformatics
– volume: 359
  start-page: 2
  year: 2012
  end-page: 12
  article-title: New insights into the mechanisms of activin action and inhibition
  publication-title: Mol Cell Endocrinol
– volume: 283
  start-page: 16743
  year: 2008
  end-page: 16751
  article-title: Suppression of inhibin biological activity by alterations in the binding site for betaglycan
  publication-title: J Biol Chem
– volume: 615
  start-page: 28
  year: 2007
  end-page: 56
  article-title: A strategy to discover genes that carry multi‐allelic or mono‐allelic risk for common diseases: a cohort allelic sums test ( )
  publication-title: Mutat Res
– volume: 20
  start-page: 490
  year: 2012
  end-page: 497
  article-title: Disease gene identification strategies for exome sequencing
  publication-title: Eur J Hum Genet
– volume: 5
  start-page: e1000384
  year: 2009
  article-title: A groupwise association test for rare mutations using a weighted sum statistic
  publication-title: PLoS Genet
– volume: 108
  start-page: 18032
  year: 2011
  end-page: 18037
  article-title: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
  publication-title: Proc Natl Acad Sci USA
– volume: 485
  start-page: 237
  year: 2012
  end-page: 241
  article-title: De novo mutations revealed by whole‐exome sequencing are strongly associated with autism
  publication-title: Nature
– volume: 285
  start-page: 36645
  year: 2010
  end-page: 36655
  article-title: Activin binds to perlecan through its pro‐region that has heparin/heparan sulfate binding activity
  publication-title: J Biol Chem
– volume: 359
  start-page: 53
  year: 2012
  end-page: 65
  article-title: Intra‐ovarian roles of activins and inhibins
  publication-title: Mol Cell Endocrinol
– volume: 3
  start-page: 97
  year: 2009
  end-page: 137
  article-title: Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management
  publication-title: Mol Oncol
– volume: 285
  start-page: 157
  year: 2009
  end-page: 165
  article-title: Activin is a potent growth suppressor of epithelial ovarian cancer cells
  publication-title: Cancer Lett
– volume: 7
  start-page: e1001322
  year: 2011
  article-title: Testing for an unusual distribution of rare variants
  publication-title: PLoS Genet
– volume: 360
  start-page: 313
  year: 1992
  end-page: 319
  article-title: Alpha‐inhibin is a tumour‐suppressor gene with gonadal specificity in mice
  publication-title: Nature
– ident: e_1_2_3_10_1
  doi: 10.1371/journal.pgen.1000384
– ident: e_1_2_3_11_1
  doi: 10.1074/jbc.M801045200
– ident: e_1_2_3_4_1
  doi: 10.1038/ejhg.2011.258
– ident: e_1_2_3_19_1
  doi: 10.1038/nrg3241
– ident: e_1_2_3_8_1
  doi: 10.1038/ng.893
– ident: e_1_2_3_7_1
  doi: 10.1074/jbc.M110.177865
– ident: e_1_2_3_2_1
  doi: 10.1158/0008-5472.CAN-04-3553
– ident: e_1_2_3_3_1
  doi: 10.1186/1471-2105-13-S14-S9
– ident: e_1_2_3_17_1
  doi: 10.1186/gb-2011-12-9-227
– ident: e_1_2_3_18_1
  doi: 10.1038/nature10166
– ident: e_1_2_3_22_1
  doi: 10.1016/j.mce.2011.06.030
– ident: e_1_2_3_6_1
  doi: 10.1016/j.ajhg.2008.06.024
– ident: e_1_2_3_14_1
  doi: 10.1371/journal.pgen.1001322
– ident: e_1_2_3_16_1
  doi: 10.1038/nature10945
– ident: e_1_2_3_12_1
  doi: 10.1038/360313a0
– ident: e_1_2_3_13_1
  doi: 10.1016/j.mrfmmm.2006.09.003
– ident: e_1_2_3_15_1
  doi: 10.1016/j.canlet.2009.05.010
– ident: e_1_2_3_5_1
  doi: 10.1016/j.mce.2011.04.024
– ident: e_1_2_3_9_1
  doi: 10.1016/j.molonc.2009.02.004
– ident: e_1_2_3_21_1
  doi: 10.1073/pnas.1115052108
– ident: e_1_2_3_20_1
  doi: 10.1038/ng.712
– ident: e_1_2_3_23_1
  doi: 10.1016/j.ajhg.2011.05.029
SSID ssj0008553
Score 2.2084823
Snippet ABSTRACT To identify novel genetic bases of early‐onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial...
To identify novel genetic bases of early-onset epithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of...
To identify novel genetic bases of early-onsetepithelial ovarian tumors, we used the trio exome sequencing strategy in a patient without familial history of...
SourceID pubmedcentral
hal
proquest
crossref
pubmed
wiley
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 294
SubjectTerms activin
Activins - biosynthesis
Biochemistry, Molecular Biology
Brief Reports
cancer
Carcinoma, Ovarian Epithelial
Cell Differentiation
Cohort Studies
Epithelial Cells - metabolism
Exome
Female
Genes
Genomics
Germ-Line Mutation
Granulosa Cells - metabolism
Humans
INHA
INHBA
inhibin
Inhibin-beta Subunits - genetics
Inhibins - biosynthesis
Life Sciences
Molecular biology
Mutation
Neoplasms, Glandular and Epithelial - genetics
Ovarian cancer
Ovarian Neoplasms - genetics
ovary
Sequence Analysis, DNA
Tumors
Young Adult
Title Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors
URI https://api.istex.fr/ark:/67375/WNG-ZJ4T3D6Z-D/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhumu.22489
https://www.ncbi.nlm.nih.gov/pubmed/24302632
https://www.proquest.com/docview/1659797808
https://search.proquest.com/docview/1499153284
https://search.proquest.com/docview/1560116099
https://normandie-univ.hal.science/hal-02375836
https://pubmed.ncbi.nlm.nih.gov/PMC4284000
Volume 35
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB21RSBeuJRboFThIh6Qsk0cO04kXipKu63YFqFdUVVClhM72lVpttpsKuCJT-Ab-RLG9m6WBVQJ3qJkcvF4xnMmHh8DPA-lLKXSKsgp4QElKgtyDNRBKjOqY6l4ZovHe4dJd0APjtnxCryar4Vx_BDtDzfjGXa8Ng4u83prQRo6bM6aDgag1KzeM0x6BhG9X3BHpYy56nqWIYTMaMtNSrYWty5Fo9WhqYW8YtT7-W-A88-6yV_xrA1Iuzfh47wprg7ltNNM807x9TeWx_9t6y24MUOq_rYzrduwoqt1uOr2rvyyDtd6s1n5O7C_h8O7eYnfa9zMfu2PS3-_Go7M4jJ_VPmWR_nHt-9HVa2n_tEFZugSz56bFSGf0AX8fnM2ntR3YbD7pv-6G8y2aAgKVC8qtiwQwxGVE6Z4abBXEudZGSdFxpSMtVJEl6UkZc5YytOSlBgLU4wPmLcppmV8D9aqcaUfgE9jFeZpUTBOQ8pDLkNdxIWO0hAfUETcg2fzrhLnjolDOM5lIox-hNWPB0-xF1sBQ57d3X4rzDlEJ5gcxclF5MEL28mtmJycmgI3zsSHwz1xckD78U5yInY82JhbgZj5di2iBJMwQ9yUevCkvYxeaaZaZKXHDcpgIomxBGP_JTImGY4ShOge3HeG1X4QoXFomPQ94Esmt9Sw5SvVaGjZwTGfxHE59OCltahLdCW6g97AHj38F-FHcB1RI3WFeBuwNp00-jEis2m-CauEvtu0fvgTWIo2Zw
link.rule.ids 230,315,786,790,891,1382,11589,27955,27956,46085,46327,46509,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7RVlAuCMorUCA8xAEpNPEjTo4Vpd0tmy2HXVH1Yjmxo12VZqvdTQU3fgK_kV_C2ElTVqBK3CJ7EsVjz8w38fgLwJtQqVJpo4OcEREwotMgx0AdJCplhiotUlc8ng3j3pgdHvPjtjbHnoVp-CG6D27WMpy_tgZuP0jvXLGGTuqz-j1GoCRdgw1mmeAssTP73DnihPOmvp6nCCJT1rGTkp2re1fi0drEVkNuWAV_-xfk_Lty8k9E60LS_l2402JJf7eZ_Htww1RbcLP5u-T3LbiVtfvm96F_gA7YDtnP6mbvfeHPSr9fTab2-Jc_rXzHdPzrx8-jamGW_tEF5tAKW8_tmY2vuEj9UX02my8ewHj_4-hDL2h_ohAUOHwceFkgyiI6J1yL0qKjmOZpSeMi5VpRozUxZalImXOeiKQkJUarBD04ZlaaG0Ufwno1q8xj8BnVYZ4UBRcsZCIUKjQFLUyUhPiAIhIevL5UpTxvuDJkw4pMpFW4dAr34BVquROw9Na93YG0bYgfMH2h8UXkwVs3CZ2Ymp_aEjTB5ZfhgTw5ZCO6F5_IPQ-2L2dJtta3kFGMaZKlVko8eNl1o93YzRBVmVmNMpjqobfH6HyNjE1XoxhBtAePmonvXogwGlquew_EypJYGdhqTzWdOP5uzPjQc4YevHOL5xpdyd44G7urJ_8j_AI2e6NsIAf94aencBsxHmvK5rZhfTmvzTPEUcv8ubOW35C3GHM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED_tQ0y8IBhfgQHhQzwgZUscO04kXiZK146120Mrpr1YTmyrFSyt2maCN_4E_kb-Es5Om1GBJvEWOZcoPvvufheffwZ4E0pppNIqyCnhASUqC3IM1EEqM6pjqXjmisd7_aQzpMfn7HwD3q_2wtT8EM0PN2sZzl9bA58qc3BNGjqqLqt9DEBptgnbNEHoYHmd6Vnjh1PG6vJ6liGGzGhDTkoOrp9dC0ebI1sMuW31--1fiPPvwsk_Aa2LSO27cGcJJf3DeuzvwYYud-FWfbjk913Y6S2Xze9D9wj9r-2x36vqpfe5PzF-txyN7e4vf1z6juj414-fp-VcL_zTK0yhJbZO7ZaNrzhH_UF1OZnNH8Cw_XHwoRMsz1AICuw-dtwUCLKIyglT3FhwlMR5ZuKkyJiSsVaKaGMkMTljKU8NMRisUnTgmFgppmX8ELbKSakfg09jFeZpUTBOQ8pDLkNdxIWO0hBfUETcg9crVYppTZUhalJkIqzChVO4B69Qy42AZbfuHJ4I24bwAbOXOLmKPHjrBqERk7MvtgKNM_G5fyQujukgbiUXouXB3mqUxNL45iJKMEuyzEqpBy-b22g2di1ElnpSoQxmeujsMTjfIGOz1ShBDO3Bo3rgmw8iNA4t1b0HfG1KrHVs_U45Hjn6bkz40HGGHrxzk-cGXYnOsDd0V0_-R_gF7Jy12uKk2__0FG4jwqN10dwebC1mlX6GKGqRP3fG8hu-jRec
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Germline+Mutations+of+Inhibins+in+Early%E2%80%90Onset+Ovarian+Epithelial+Tumors&rft.jtitle=Human+mutation&rft.au=Tournier%2C+Isabelle&rft.au=Marlin%2C+R%C3%A9gine&rft.au=Walton%2C+Kelly&rft.au=Charbonnier%2C+Fran%C3%A7oise&rft.date=2014-03-01&rft.issn=1059-7794&rft.eissn=1098-1004&rft.volume=35&rft.issue=3&rft.spage=294&rft.epage=297&rft_id=info:doi/10.1002%2Fhumu.22489&rft.externalDBID=10.1002%252Fhumu.22489&rft.externalDocID=HUMU22489
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1059-7794&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1059-7794&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1059-7794&client=summon